Based on the provided sources, it is not clear whether there is a readily available patent for nicardipine formulation.

The first source, DrugPatentWatch, provides information on various drug patents, including Nicardipine. However, it requires a subscription to access detailed information about specific patents. Without a subscription, it is not possible to determine if there is a readily available patent for nicardipine formulation [1].

The second source, a book chapter from the National Center for Biotechnology Information (NCBI), discusses the pharmacokinetics and pharmacodynamics of nicardipine. While it provides valuable information about the drug, it does not mention anything about the availability of a patent for its formulation [2].

The third source, an article from the European Journal of Pharmaceutics and Biopharmaceutics, discusses the development and evaluation of a controlled-release formulation of nicardipine. Although the article mentions the formulation of nicardipine, it does not provide information about the patent status of the formulation [3].

In conclusion, based on the provided sources, it is not possible to determine if there is a readily available patent for nicardipine formulation. To obtain detailed information about the patent status, it may be necessary to consult additional sources or access the specific patent databases mentioned in the first source.

Sources:
[1] DrugPatentWatch. Nicardipine. Retrieved from https://www.drugpatentwatch.com/p/tradename/NICARDIPINE
[2] National Center for Biotechnology Information (NCBI). Nicardipine. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482473/
[3] European Journal of Pharmaceutics and Biopharmaceutics. Development and evaluation of a controlled-release formulation of nicardipine. Retrieved from http://www.ingentaconnect.com/content/govi/pharmaz/2003/00000058/00000001/art00008?crawler=true